{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:32:20Z","timestamp":1793939540382,"version":"4.8.0"},"reference-count":45,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,5]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Current cell and gene therapies lack clinically practical mechanisms to selectively promote or suppress therapeutic cells in vivo, a limitation that is particularly acute in patients requiring ongoing immunosuppression. This includes gene therapy for immune dysregulation syndromes, and antigen-specific or chimeric antigen receptor (CAR) T-cell therapy for patients requiring immunosuppression (eg, transplant recipients), in which both pathogenic and therapeutic cells may be suppressed. Here, we develop a multiplex prime-editing platform that converts commonly used immunosuppressive drugs into tools for in vivo control of T-cell therapies via defined, pathway-specific drug resistance. Focusing initially on gene therapy, prime editing efficiently edited loci of multiple pathogenic variants associated with immune dysregulation in primary human T-cells and corrected the HAVCR2 driver mutation in T cells from multiple patients with subcutaneous panniculitis-like T-cell lymphoma (SPTCL). Comprehensive genomic, transcriptional, immunophenotypic, and clonal analyses demonstrated minimal off-target perturbation. Multiplexed gene correction and drug-resistance editing of T-cells from patients with SPTCL enabled selective in vivo expansion of corrected cells under immunosuppressive pressure in humanized mouse models and exhibited retained sensitivity to alternative agents permitting rapid in vivo suppression. Extending this approach, prime-edited, drug-resistant antigen-specific and CAR T cells retained effector function despite pharmacologic immunosuppression, demonstrating the generalizability of this platform to diverse cellular therapies. Together, these findings establish multiplex prime editing as a promising preclinical framework for generating drug-controllable T-cell therapies, enabling selective in vivo modulation in settings in which immunosuppression cannot be withdrawn.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2026033156","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:23:51Z","timestamp":1785327831000},"page":"2354-2367","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Prime editing enables drug-controllable T-cell therapies with clinical immunosuppression"],"prefix":"10.1182","volume":"148","author":[{"given":"Esther","family":"Bandala-Sanchez","sequence":"first","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2527-269X","authenticated-orcid":false,"given":"Emma V.","family":"Petley","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Ramsay","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Hilton","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"White","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7363-0068","authenticated-orcid":false,"given":"Naiara G.","family":"Bediaga","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie S.","family":"Li Wai Suen","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0299-3301","authenticated-orcid":false,"given":"Shalin H.","family":"Naik","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-7894","authenticated-orcid":false,"given":"Ashleigh S.","family":"Davey","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5846-6469","authenticated-orcid":false,"given":"Matthew E.","family":"Call","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7684-5841","authenticated-orcid":false,"given":"Melissa J.","family":"Call","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6655-9876","authenticated-orcid":false,"given":"Carrie","family":"van der Weyden","sequence":"additional","affiliation":[{"name":"3Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia"},{"name":"4Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3855-8232","authenticated-orcid":false,"given":"Lucy C.","family":"Fox","sequence":"additional","affiliation":[{"name":"3Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia"},{"name":"4Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ritchie","sequence":"additional","affiliation":[{"name":"3Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia"},{"name":"4Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Sutrave","sequence":"additional","affiliation":[{"name":"5Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"},{"name":"6Department of Haematology, Westmead Hospital, Westmead, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Micklethwaite","sequence":"additional","affiliation":[{"name":"5Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"},{"name":"6Department of Haematology, Westmead Hospital, Westmead, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"5Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"},{"name":"6Department of Haematology, Westmead Hospital, Westmead, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3785-7759","authenticated-orcid":false,"given":"Samantha","family":"Chan","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, Australia"},{"name":"7Immunology and Allergy, The Royal Melbourne Hospital, Melbourne, Australia"},{"name":"8Department of Infectious Diseases and Immunology, Austin Hospital, Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-5720","authenticated-orcid":false,"given":"Andrew W.","family":"Roberts","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, Australia"},{"name":"3Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia"},{"name":"4Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Slade","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, Australia"},{"name":"7Immunology and Allergy, The Royal Melbourne Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-2432","authenticated-orcid":false,"given":"Thomas E.","family":"Lew","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, Australia"},{"name":"3Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia"},{"name":"4Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles B.","family":"Horton","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"17","key":"2026110511215447100_bib1","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1182\/blood-2008-09-177923","article-title":"Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency","volume":"113","author":"Neven","year":"2009","journal-title":"Blood"},{"issue":"15","key":"2026110511215447100_bib2","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2502754","article-title":"Long-term safety and efficacy of gene therapy for adenosine deaminase deficiency","volume":"393","author":"Booth","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"2026110511215447100_bib3","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.jaci.2018.12.1010","article-title":"Hematopoietic stem cell transplantation for CD40 ligand deficiency: results from an EBMT\/ESID-IEWP-SCETIDE-PIDTC study","volume":"143","author":"Ferrua","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"25","key":"2026110511215447100_bib4","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2015-12-684498","article-title":"The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis","volume":"127","author":"Hartz","year":"2016","journal-title":"Blood"},{"issue":"668","key":"2026110511215447100_bib5","doi-asserted-by":"crossref","first-page":"eabn5811","DOI":"10.1126\/scitranslmed.abn5811","article-title":"Therapeutic gene editing of T cells to correct CTLA-4 insufficiency","volume":"14","author":"Fox","year":"2022","journal-title":"Sci Transl Med"},{"issue":"24","key":"2026110511215447100_bib6","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1182\/bloodadvances.2025017097","article-title":"Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction","volume":"9","author":"Rubinstein","year":"2025","journal-title":"Blood Adv"},{"issue":"5235","key":"2026110511215447100_bib7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.270.5235.475","article-title":"T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years","volume":"270","author":"Blaese","year":"1995","journal-title":"Science"},{"issue":"1","key":"2026110511215447100_bib8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood.V91.1.30","article-title":"Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency","volume":"91","author":"Onodera","year":"1998","journal-title":"Blood"},{"issue":"3","key":"2026110511215447100_bib9","doi-asserted-by":"crossref","first-page":"e13545","DOI":"10.15252\/emmm.202013545","article-title":"Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper-IgM syndrome","volume":"13","author":"Vavassori","year":"2021","journal-title":"EMBO Mol Med"},{"issue":"3","key":"2026110511215447100_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2017.11.050","article-title":"T-cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations","volume":"142","author":"Ghosh","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2026110511215447100_bib11","doi-asserted-by":"crossref","first-page":"e1249","DOI":"10.1002\/cti2.1249","article-title":"Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant","volume":"10","author":"Gottlieb","year":"2021","journal-title":"Clin Transl Immunol"},{"issue":"2","key":"2026110511215447100_bib12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/bjh.18828","article-title":"Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed\/refractory solid organ transplant-related PTLD","volume":"202","author":"McKenna","year":"2023","journal-title":"Br J Haematol"},{"issue":"12","key":"2026110511215447100_bib13","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s41571-025-01072-4","article-title":"Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities","volume":"22","author":"Petri","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"2026110511215447100_bib14","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1016\/j.ymthe.2024.06.022","article-title":"Immunosuppressant therapy averts rejection of allogeneic FKBP1A-disrupted CAR-T cells","volume":"32","author":"Maldini","year":"2024","journal-title":"Mol Ther"},{"issue":"1","key":"2026110511215447100_bib15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ymthe.2020.09.011","article-title":"CRISPR-Cas9-edited tacrolimus-resistant antiviral T cells for advanced adoptive immunotherapy in transplant recipients","volume":"29","author":"Amini","year":"2021","journal-title":"Mol Ther"},{"issue":"2","key":"2026110511215447100_bib16","doi-asserted-by":"crossref","first-page":"100054","DOI":"10.1016\/j.bict.2026.100054","article-title":"Precision editing of cyclophilin A generates cyclosporine- and voclosporin-resistant cellular therapies","volume":"2","author":"Wobma","year":"2026","journal-title":"Blood Immunol Cell Ther"},{"issue":"4","key":"2026110511215447100_bib17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa1000164","article-title":"Efficacy of gene therapy for X-linked severe combined immunodeficiency","volume":"363","author":"Hacein-Bey-Abina","year":"2010","journal-title":"N Engl J Med"},{"issue":"5644","key":"2026110511215447100_bib18","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"issue":"14","key":"2026110511215447100_bib19","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1056\/NEJMoa2400442","article-title":"Lentiviral gene therapy for cerebral adrenoleukodystrophy","volume":"391","author":"Eichler","year":"2024","journal-title":"N Engl J Med"},{"issue":"22","key":"2026110511215447100_bib20","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-cell lymphoma after CAR T-cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"2026110511215447100_bib21","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13059-021-02462-4","article-title":"Effective control of large deletions after double-strand breaks by homology-directed repair and dsODN insertion","volume":"22","author":"Wen","year":"2021","journal-title":"Genome Biol"},{"issue":"42","key":"2026110511215447100_bib22","doi-asserted-by":"crossref","first-page":"eabo7676","DOI":"10.1126\/sciadv.abo7676","article-title":"Comprehensive analysis and accurate quantification of unintended large gene modifications induced by CRISPR-Cas9 gene editing","volume":"8","author":"Park","year":"2022","journal-title":"Sci Adv"},{"issue":"7603","key":"2026110511215447100_bib23","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"issue":"7681","key":"2026110511215447100_bib24","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u00b7T to G\u00b7C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"issue":"7785","key":"2026110511215447100_bib25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"issue":"2","key":"2026110511215447100_bib26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0167-4781(94)90029-9","article-title":"Gene amplification and dual point mutations of mouse IMP dehydrogenase associated with cellular resistance to mycophenolic acid","volume":"1217","author":"Lightfoot","year":"1994","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"2026110511215447100_bib27","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1074\/jbc.270.10.5057","article-title":"Methotrexate-resistant variants of human dihydrofolate reductase with substitutions of leucine 22. Kinetics, crystallography, and potential as selectable markers","volume":"270","author":"Lewis","year":"1995","journal-title":"J Biol Chem"},{"issue":"12","key":"2026110511215447100_bib28","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41588-018-0251-4","article-title":"Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome","volume":"50","author":"Gayden","year":"2018","journal-title":"Nat Genet"},{"issue":"18","key":"2026110511215447100_bib29","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1182\/blood.2023021788","article-title":"Current and upcoming treatment approaches to uncommon subtypes of PTCL (EATL, MEITL, SPTCL, and HSTCL)","volume":"144","author":"Marchi","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2026110511215447100_bib30","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nmeth.4278","article-title":"CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets","volume":"14","author":"Tsai","year":"2017","journal-title":"Nat Methods"},{"issue":"6244","key":"2026110511215447100_bib31","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/341755a0","article-title":"A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin","volume":"341","author":"Siekierka","year":"1989","journal-title":"Nature"},{"issue":"32","key":"2026110511215447100_bib32","doi-asserted-by":"crossref","first-page":"18935","DOI":"10.1074\/jbc.270.32.18935","article-title":"FK506 binding protein mutational analysis. Defining the surface residue contributions to stability of the calcineurin co-complex","volume":"270","author":"Futer","year":"1995","journal-title":"J Biol Chem"},{"issue":"3","key":"2026110511215447100_bib33","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jmb.2007.07.076","article-title":"Increasing methotrexate resistance by combination of active-site mutations in human dihydrofolate reductase","volume":"373","author":"Volpato","year":"2007","journal-title":"J Mol Biol"},{"issue":"6","key":"2026110511215447100_bib34","doi-asserted-by":"crossref","first-page":"e65519","DOI":"10.1371\/journal.pone.0065519","article-title":"Engineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategy","volume":"8","author":"Jonnalagadda","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"2026110511215447100_bib35","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/gt.2009.131","article-title":"In vivo selection of human embryonic stem cell-derived cells expressing methotrexate-resistant dihydrofolate reductase","volume":"17","author":"Gori","year":"2010","journal-title":"Gene Ther"},{"issue":"7978","key":"2026110511215447100_bib36","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41586-023-06496-5","article-title":"Epitope editing enables targeted immunotherapy of acute myeloid leukaemia","volume":"621","author":"Casirati","year":"2023","journal-title":"Nature"},{"issue":"9","key":"2026110511215447100_bib37","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/s41434-021-00220-6","article-title":"Targeted multi-epitope switching enables straightforward positive\/negative selection of CAR T cells","volume":"28","author":"Mosti","year":"2021","journal-title":"Gene Ther"},{"issue":"714","key":"2026110511215447100_bib38","doi-asserted-by":"crossref","first-page":"eadi1145","DOI":"10.1126\/scitranslmed.adi1145","article-title":"Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy","volume":"15","author":"Wellhausen","year":"2023","journal-title":"Sci Transl Med"},{"issue":"suppl 1","key":"2026110511215447100_bib39","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1182\/blood-2024-202480","article-title":"Epitope editing combined with extended schedule anti-KIT antibody treatment allows immune-based in vivo selection of multiplex genome-engineered cells","volume":"144","author":"Casirati","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026110511215447100_bib40","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nm0296-216","article-title":"T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients","volume":"2","author":"Riddell","year":"1996","journal-title":"Nat Med"},{"issue":"14","key":"2026110511215447100_bib41","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa2405541","article-title":"Hematologic cancer after gene therapy for cerebral adrenoleukodystrophy","volume":"391","author":"Duncan","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"2026110511215447100_bib42","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/blood-2005-08-3503","article-title":"Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation","volume":"107","author":"Berger","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2026110511215447100_bib43","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s12033-024-01070-4","article-title":"The future of gene therapy: a review of in vivo and ex vivo delivery methods for genome editing-based therapies","volume":"67","author":"Volodina","year":"2025","journal-title":"Mol Biotechnol"},{"issue":"10","key":"2026110511215447100_bib44","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1172\/JCI200317922","article-title":"In vivo selection of MGMT(P140K) lentivirus-transduced human NOD\/SCID repopulating cells without pretransplant irradiation conditioning","volume":"112","author":"Zielske","year":"2003","journal-title":"J Clin Invest"},{"issue":"10","key":"2026110511215447100_bib45","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1172\/JCI200318782","article-title":"Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model","volume":"112","author":"Neff","year":"2003","journal-title":"J Clin Invest"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/19\/2354\/2597952\/blood_bld-2026-033156-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/19\/2354\/2597952\/blood_bld-2026-033156-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:22:04Z","timestamp":1793895724000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/19\/2354\/569935\/Prime-editing-enables-drug-controllable-T-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,5]]},"references-count":45,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,11,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2026033156","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11,5]]},"published":{"date-parts":[[2026,11,5]]}}}